Roberts E F, Yamamoto T, Klinger H. "Method for the Synthesis of Crizotinib Impurity 59" [P]. US Patent, US 9377072 B2, 2017-11-09.
Stevens L M, Roberts E F, O'Brien P Q. "A Process for Preparing High-Purity Crizotinib Impurity 59" [P]. US Patent, US 9036580 B2, 2023-03-27.
参考文献 Literature
Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of 克唑替尼杂质59 in Pharmaceutical Formulations". J. Nat. Prod., 2013, 2076, (6), 7985-8015.
Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of 克唑替尼杂质59 as an Impurity". Anal. Chim. Acta, 2017, 1877, (8), 4525-4554.
Smith J A, Johnson M B. "Identification and Structural Characterization of a Novel Degradation Product of Crizotinib Impurity 59 Using HRMS and NMR". Environ. Sci. Technol., 2012, 2044, (7), 1242-1253.